NBNima Badie

Nima Badie

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Nima Badie has a total of 76 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Initial experience of atrial helix-fixation leadless pacemakers with extended battery longevity

    by Ulrika Birgersdotter-Green, James E. Ip, Nima Badie, Kyungmoo Ryu, Devi G. Nair

  • Open Access

    Atrioventricular synchrony maintained by a dual-chamber leadless pacemaker in real-world conditions

    by Pascal Defaye, Vivek Y Reddy, James E Ip, Rahul N Doshi, Derek V Exner, Robert C Canby, Maria Grazia Bongiorni, Morio Shoda, Gerhard Hindricks, Mayer Y Rashtian, et al.

    Aims: A dual-chamber leadless pacemaker (LP) system relies on a beat-to-beat, wireless, implant-to-implant (i2i™) communication between implanted devices in the right atrium and right ventricle (A-to-V and V-to-A). Atrioventricular (AV) synchrony was evaluated during an ambulatory 24 h period of daily living to determine if its effectiveness can be maintained under real-world conditions. Methods and results: A prospective, single-arm, multicentre clinical study (ClinicalTrials.gov identifier NCT05252702) evaluated the overall safety and performance of the dual-chamber LPs in patients with standard indications for dual-chamber pacing. Following the 3-month visit, eligible patients wore 12-lead Holter monitors for 24 h while resuming the activities of daily living while under clinically driven programmed settings. Leadless pacemaker diagnostic data were interrogated when patients returned to the clinic. An independent Holter core laboratory adjudicated the proportion of synchronous beats (PR intervals within paced and sensed AV delay bounds). Relationships between AV synchrony and i2i communication success rate, implant indication, heart rate, and AV event type were evaluated. Among 47 analysable patients, mean AV synchrony was achieved in 96.7% of beats, exceeding mean A-to-V and V-to-A transmission success rates of 93.4% and 92.1%, respectively. There were no significant differences in AV synchrony between sinus node and AV block patients. Across all AV paced/sensed cycle combinations and heart rate ranges (including >100 b.p.m.), AV synchrony was sustained >90% in an ambulatory real-world setting. Conclusion: A dual-chamber leadless pacing system demonstrated >96% overall AV synchrony for a 24 h period of daily living while programmed to clinically appropriate settings, thus showing that true dual-chamber DDD(R) pacing can be maintained in a real-world environment.


  • Open Access

    Battery longevity of a helix-fixation dual-chamber leadless pacemaker: results from the AVEIR DR i2i Study

    by Vivek Y Reddy, Rahul Doshi, James E Ip, Pascal Defaye, Derek V Exner, Robert Canby, Morio Shoda, Maria G Bongiorni, Gerhard Hindricks, Petr Neužil, et al.

    Aims: A dual-chamber leadless pacemaker (LP) system that employs distinct atrial and ventricular LP devices (ALP, VLP) has been introduced to clinical practice. Proprietary, low-energy, implant-to-implant (i2i) communication at each beat enables the devices to maintain synchronous atrioventricular sensing and pacing. We evaluated device longevities and contributing factors, such as i2i communication. Methods and results: Patients meeting dual-chamber pacing indications received the dual-chamber LP system as part of a prospective, multi-centre, international clinical trial (Aveir DR i2i Study, NCT05252702). Programming and diagnostics were interrogated from all de novo, non-revised, dual-chamber programmed devices at 12 months post-implant. This analysis included 302 patients (65% male; age 70 ± 13 years; weight 80 ± 19 kg; intrinsic heart rate 55 ± 7 bpm; 58% sinus node dysfunction, 27% atrioventricular block). At 12 months, devices were programmed to dual-chamber pacing (DDD(R) or DDI(R)) at a median 60 bpm rate, median 1.25 V pulse amplitude in ALP and 1.5 V in VLP, median 0.4 ms pulse width, and median i2i signal setting level 5 out of 7. Median ALP and VLP remaining battery longevities at 12 months were 4.3 and 9.1 years, with median total ALP and VLP longevities of 5.3 and 9.9 years. Base rate, pulse amplitude, pacing percentage, event rate, impedance, and i2i setting level all exhibited significant correlations with ALP and VLP longevities (P < 0.001). Programming i2i setting levels below 7 produced the greatest longevity savings. Conclusion: The first dual-chamber LP demonstrated adequate projected battery longevity after 12 months of use. Patient-specific device programming considerations, unique to leadless devices, may extend longevity.


  • Open Access

    Atrial helix-fixation leadless pacemaker: real-world single-chamber implant experience

    by Devi G. Nair, Ken W. Lee, Nima Badie, Leonard Ganz, Kyungmoo Ryu, Cyrus A. Hadadi

    Background Single -chamber ventricular leadless pacemakers (LPs) are well established. A dual-chamber LP system has recently become available with distinct atrial and ventricular devices. Single-chamber atrial pacing with transvenous devices is infrequent due to future upgrade concerns. This multi-center study evaluated the initial real-world use of the atrial LP by itself to treat isolated sinus node dysfunction (SND). Methods SND patients with normal PR interval and AV conduction to be implanted with atrial LPs after commercial US release were consecutively included. Procedural characteristics were evaluated, and electrical parameters were measured during pre-fixation mapping, post-fixation tether mode, after LP release, and before patient discharge. Acute, 30-day procedure- or device-related complications were noted. Results Aveir AR devices were implanted per standard local practice (N = 75 patients; 3 centers; 72 ± 13 years; 52% male; 92% de novo) with 100% success and placed predominantly in the right atrial appendage base (83%). The total procedure duration (from first incision to final suture) was 36 ± 33 min and the cumulative fluoroscopy duration was 7 ± 8 min. Pre-fixation mapping made repositioning unnecessary in 95% of implants. Pacing capture threshold at 0.4 ms pulse width, sensed amplitude, and impedance values of 0.6 ± 0.6 V, 2.9 ± 1.5 mV, and 329 ± 46 Ω, respectively, were measured prior to patient discharge. Capture threshold and sensed amplitude had improved significantly from LP release to patient discharge. No acute complications were observed. Conclusion This initial real-world experience implanting the helix-fixation, single-chamber, atrial LP in SND patients demonstrated safe and efficient implantation, clinically acceptable electrical metrics, and no acute complications. Graphical Abstract


  • Commercial Implant Experience of a Helix‐Fixation Dual‐Chamber Leadless Pacemaker

    by Cyrus A. Hadadi, Ken W. Lee, Monica Lo, Mayer Rashtian, Derek V. Exner, Blandine Mondésert, Athanasios Thomaides, Nebu Alexander, Zayd Eldadah, Nima Badie, et al.

    Introduction: The AVEIR DR pacemaker (Abbott) is a dual‐chamber leadless pacemaker (LP) system that includes right atrial and right ventricular helix‐fixation LPs (ALP, VLP), with atrioventricular synchrony maintained via wireless communication between the two devices. The initial, multi‐center commercial implant experience of the AVEIR DR dual‐chamber LP system has yet to be evaluated.Methods: Patients indicated for dual‐chamber pacing after US commercial release were consecutively included. Implant procedural characteristics were evaluated, and electrical parameters were measured during pre‐fixation mapping, post‐fixation tether mode, after LP release, and before patient discharge. Any acute procedure‐ or device‐related complications within 30 days were noted.Results: Patients were implanted with AVEIR DR per standard practice (N = 175 at 8 centers; 72 ± 11 years; 60% male; 62% sinus node dysfunction, 37% AV block; 83% de novo implants). ALPs were implanted predominantly in the base of the right atrial appendage (82%), VLPs in the mid‐to‐apical right ventricular septum (94%). Pre‐fixation mapping allowed repositioning to be avoided in 95% of ALPs and VLPs. The total procedure duration was 64 ± 33 min, from initial incision to final suture, with a cumulative fluoroscopy duration of 13 ± 8 min. In both LPs, capture thresholds and sensed amplitudes improved significantly before patient discharge (ALP 1.2 ± 1.0 V, 2.1 ± 1.1 mV; VLP 0.8 ± 0.6 V, 9.5 ± 3.8 mV). At 30 days post‐implant, 99% of patients were complication‐free.Conclusion: The initial commercial experience of the helix‐fixation, dual‐chamber LP system demonstrated safe and efficient implantation with clinically acceptable electrical metrics and minimal acute complications.


  • Open Access

    Atrioventricular Synchrony Delivered by a Dual-Chamber Leadless Pacemaker System

    by James E. Ip, Mayer Rashtian, Derek V. Exner, Vivek Y. Reddy, Rahul Doshi, Nima Badie, Jordan R. Nevo, Aditya Goil, Pascal Defaye, Robert Canby, et al.

    BACKGROUND: A dual-chamber leadless pacemaker system has been designed for atrioventricular synchronous pacing using wireless, beat-to-beat, implant-to-implant (i2i) communication between distinct atrial and ventricular leadless pacemakers. The atrioventricular synchrony achieved across various ambulatory scenarios has yet to be systematically evaluated. METHODS: A prospective, single-arm, unblinded, multicenter, international clinical trial of the leadless pacemaker system was conducted in patients with a conventional dual-chamber pacing indication enrolled from February 2022 to March 2023. Leadless pacemaker systems were implanted, and 12-lead Holter electrocardiographic recordings were collected 3 months after implantation over various postures/activities: sitting, supine, left lateral recumbent, right lateral recumbent, standing, normal walk, and fast walk. An independent Holter core laboratory performed a manual adjudication of the percent of atrioventricular synchronous beats using the standard 300-millisecond PR interval limit. Atrium-to-ventricle and ventricle-to-atrium i2i communication success rates were also assessed. Post hoc summary statistics describing the relationships between atrioventricular synchrony and i2i success, posture/activity, implantation indication, atrioventricular event, and heart rate were calculated. RESULTS: In the evaluable population (n=384 of 464 enrolled [83%]; 61% male; age, 70 years; weight, 82 kg; 60% ejection fraction; 95% of beats evaluable), the mean atrioventricular synchrony of 98% of beats observed across all postures using the standard 300-millisecond limit was greater than both atrial-to-ventricular i2i (94%) and ventricular-to-atrial i2i (94%; P 95% of evaluable beats across all postures/activities, implantation indications, atrioventricular paced/sensed event combinations, and heart rate ranges (including >100 bpm). CONCLUSIONS: This dual-chamber leadless pacemaker system demonstrated atrioventricular synchrony in 98% of evaluable beats at 3 months after implantation. Atrioventricular synchrony was maintained across postures/activities and remained robust for heart rates >100 bpm.


  • Open Access

    Early Real-world Implant Experience with a Helix-fixation Ventricular Leadless Pacemaker

    by Devi G. Nair, Derek V. Exner, Vivek Y. Reddy, Nima Badie, David Ligon, Marc A. Miller, Bridget Lee, Brandon Doty, Athanasios Thomaides, Zayd Eldadah, et al.

    Background Roughly 1 in 6 patients receiving conventional transvenous pacemaker systems experience significant complications within 1 year of implant, mainly due to the transvenous lead and subcutaneous pocket. A new helix-fixation single-chamber ventricular leadless pacemaker (LP) system capable of pre-deployment exploratory electrical mapping is commercially available. Such an LP may mitigate complications while streamlining the implantation. Objectives Evaluate the initial real-world implant experience of the helix-fixation LP following its commercial release. Methods In patients indicated for single-chamber right ventricular pacing, helix-fixation Aveir VR LPs (Abbott, Abbott Park, IL) were implanted using the dedicated loading tool, introducer, and delivery catheter. Implant procedural characteristics, electrical parameters, and any 30-day procedure-related adverse events of consecutive implant attempts were retrospectively evaluated. Results A total of 167 patients with Class I indication for permanent pacing received implants in 4 North American centers (57% male, 70 years old). Pre-fixation electrical mapping of potential sites allowed repositioning to be avoided in 95.7% of patients. Median [interquartile range] LP procedure and fluoroscopy durations were 25.5 min [20.0, 35.0] and 5.7 min [4.0, 9.2], respectively. Pacing capture threshold, sensed R-wave amplitude, and impedance were 0.8 V [0.5, 1.3], 9.0 mV [6.0, 12.0], and 705 Ω [550, 910], respectively. Implantation was successful in 98.8% of patients, with 98.2% free from acute adverse events. Conclusion The initial, real-world experience of the helix-fixation ventricular leadless pacemaker demonstrated safe and efficient implantation with minimal repositioning, viable electrical metrics, and limited acute complications.


  • Retrieval of Chronically Implanted Dual-chamber Leadless Pacemakers in an Ovine Model

    by Rajesh S. Banker, Marian K. Rippy, Nicole Cooper, Petr Neužil, Derek V. Exner, Devi G. Nair, Daniel F. Booth, David Ligon, Nima Badie, Mark Krans, et al.

    BACKGROUND: The clinical utilization of leadless pacemakers (LPs) as an alternative to traditional transvenous pacemakers is likely to increase with the advent of dual-chamber LP systems. Since device retrieval to allow LP upgrade or replacement will become an important capability, the first such dual-chamber, helix-fixation LP system (Aveir DR; Abbott, Abbott Park, IL) was specifically designed to allow catheter-based retrieval. In this study, the preclinical performance and safety of retrieving chronically implanted dual-chamber LPs was evaluated. METHODS: Atrial and ventricular LPs were implanted in the right atrial appendage and right ventricular apex of 9 healthy ovine subjects. After ≈2 years, the LPs were retrieved using a dedicated transvenous retrieval catheter (Aveir Retrieval Catheter; Abbott) by snaring, docking, and unscrewing from the myocardium. Comprehensive necropsy/histopathology studies were conducted to evaluate device- and procedure-related outcomes. RESULTS: At a median of 1.9 years postimplant (range, 1.8–2.6), all 18 of 18 (100%) LPs were retrieved from 9 ovine subjects without complications. The median retrieval procedure duration for both LPs, from first-catheter-in to last-catheter-out, was 13.3 minutes (range, 2.5–36.4). Postretrieval, all right atrial, and right ventricular implant sites demonstrated minimal tissue disruption, with intact fibrous tissue limited to the distal device body. No significant device-related trauma, perforation, pericardial effusion, right heart or tricuspid valve injury, or chronic pulmonary thromboembolism were observed at necropsy. CONCLUSIONS: This preclinical study demonstrated the safe and effective retrieval of chronically implanted, helix-fixation, dual-chamber LP systems, paving the way for clinical studies of LP retrieval.


  • Open Access

    Electrocardiographic imaging demonstrates electrical synchrony improvement by dynamic atrioventricular delays in patients with left bundle branch block and preserved atrioventricular conduction

    by Peter H Waddingham, Jan O Mangual, Michele Orini, Nima Badie, Amal Muthumala, Simon Sporton, Luke C McSpadden, Pier D Lambiase, Anthony W C Chow

    Cardiac resynchronization therapy programmed to dynamically fuse pacing with intrinsic conduction using atrioventricular (AV) timing algorithms (e.g. SyncAV) has shown promise; however, mechanistic data are lacking. This study assessed the impact of SyncAV on electrical dyssynchrony across various pacing modalities using non-invasive epicardial electrocardiographic imaging (ECGi). Twenty-five patients with left bundle-branch block (median QRS duration (QRSd) 162.7 ms) and intact AV conduction (PR interval 174.0 ms) were prospectively enrolled. ECGi was performed acutely during biventricular pacing with fixed nominal AV delays (BiV) and using SyncAV (optimized for the narrowest QRSd) during: BiV + SyncAV, LV-only single-site (LVSS + SyncAV), MultiPoint pacing (MPP + SyncAV), and LV-only MPP (LVMPP + SyncAV). Dyssynchrony was quantified via ECGi (LV activation time, LVAT; RV activation time, RVAT; LV electrical dispersion index, LVEDi; ventricular electrical uncoupling index, VEU; and biventricular total activation time, VVtat). Intrinsic conduction LVAT (124 ms) was significantly reduced by BiV pacing (109 ms) (P = 0.001) and further reduced by LVSS + SyncAV (103 ms), BiV + SyncAV (103 ms), LVMPP + SyncAV (95 ms), and MPP + SyncAV (90 ms). Intrinsic RVAT (93 ms), VVtat (130 ms), LVEDi (36 ms), VEU (50 ms), and QRSd (163 ms) were reduced by SyncAV across all pacing modes. More patients exhibited minimal LVAT, VVtat, LVEDi, and QRSd with MPP + SyncAV than any other modality. Dynamic AV delay programming targeting fusion with intrinsic conduction significantly reduced dyssynchrony, as quantified by ECGi and QRSd for all evaluated pacing modes. MPP + SyncAV achieved the greatest synchrony overall but not for all patients, highlighting the value of pacing mode individualization during fusion optimization. Dynamic atrioventricular delays targeting fusion with intrinsic conduction reduce electrical dyssynchrony.


  • Wireless Communication Between Paired Leadless Pacemakers for Dual-Chamber Synchrony

    by Daniel J. Cantillon, Alok Gambhir, Rajesh Banker, Mayer Rashtian, Rahul Doshi, Nima Badie, Daniel Booth, Weiqun Yang, Peter Nee, Matthew Fishler, et al.

    Background: Leadless pacemakers (LPs) can mitigate conventional pacemaker complications related to the transvenous leads and subcutaneous pocket surrounding the pulse generator. Although single-chamber leadless pacing has been established, multichamber pacing requires wireless bidirectional communication across multiple LPs to maintain synchrony. This preclinical study demonstrates the chronic performance of implant-to-implant (i2i) communication that achieves synchronous, dual-chamber pacing with 2 LPs. Methods: The i2i communication modality employs subthreshold electrical signals conducted between implanted LPs through the blood and myocardial tissue on a beat-by-beat basis. Right atrial and right ventricular LPs were implanted in 9 ovine subjects. The i2i transmission performance was evaluated 13 weeks after implant. Results: Right atrial and right ventricular LPs were implanted successfully and without complication in 9 ovine subjects. A total of 8715±457 right atrial-to-right ventricular and right ventricular-to-right atrial transmissions were sent per hour, with a success rate of 99.2±0.9%. Of periods with i2i communication failure when DDD pacing was not possible, 97.3±1.8% were resolved within 6 s. Conclusions: For the first time, synchronized, dual-chamber pacing has been demonstrated in a chronic preclinical feasibility study by 2 leadless pacemakers using beat-to-beat, wireless communication, achieving a success rate of 99.2%.